Atossa Therapeutics (ATOS)
2.72
+0.19 (7.51%)
Upcoming Events
Latest Headlines
Atossa Therapeutics attaches CVRs to each share of common stock
October 19, 2026 8:04 AM - StreetInsider
Atossa Therapeutics Common Stock to Begin Trading with Stapled Contingent Value Rights After Close of Business Today
October 19, 2026 8:00 AM - PR NewsWire
Form 8-K ATOSSA THERAPEUTICS, For: Oct 08
October 9, 2026 8:15 AM - SEC Filing
Atossa Therapeutics sets CVR plan tied to potential FDA voucher
October 9, 2026 8:01 AM - StreetInsider
Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher Value
October 9, 2026 8:00 AM - PR NewsWire
Atossa Therapeutics plans CVR tied to rare pediatric voucher
September 29, 2026 8:02 AM - StreetInsider
Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher
September 29, 2026 8:01 AM - PR NewsWire
Form 8-K ATOSSA THERAPEUTICS, For: Sep 29
September 29, 2026 8:00 AM - SEC Filing
Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging
September 24, 2026 8:00 AM - PR NewsWire
Form 8-K ATOSSA THERAPEUTICS, For: Sep 18
September 18, 2026 5:00 PM - SEC Filing
Atossa Genetics (ATOS) Tops Q2 EPS by 10c
August 7, 2026 8:59 AM - StreetInsider
Form 8-K ATOSSA THERAPEUTICS, For: Aug 07
August 7, 2026 8:45 AM - SEC Filing
Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
August 7, 2026 8:45 AM - PR NewsWire
Form 10-Q ATOSSA THERAPEUTICS, For: Jun 30
August 7, 2026 8:31 AM - SEC Filing
Atossa preclinical study on endoxifen compounds published in npj
July 28, 2026 8:30 AM - StreetInsider
Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer
July 28, 2026 8:30 AM - PR NewsWire
Full Article List
